First Horizon Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

First Horizon Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$10.8K	Sell	345 -25	-7%	-$815	﹤0.01%	1651
2025 Q1	$12.4K	Hold	370	–	–	﹤0.01%	1518
2024 Q4	$14.5K	Hold	370	–	–	﹤0.01%	1457
2024 Q3	$14.6K	Hold	370	–	–	﹤0.01%	1497
2024 Q2	$14.4K	Hold	370	–	–	﹤0.01%	1398
2024 Q1	$15.9K	Sell	370 -200	-35%	-$9.2K	﹤0.01%	1422
2023 Q4	$26.3K	Hold	570	–	–	﹤0.01%	1226
2023 Q3	$19.5K	Hold	570	–	–	﹤0.01%	1263
2023 Q2	$21.9K	Buy	570 +370	+185%	+$14.7K	﹤0.01%	1236
2023 Q1	$7.16K	Buy	+200	New	+$7.39K	﹤0.01%	1688

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Horizon Advisors's XENE Position: Q2 2025 in Review

First Horizon Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 6.8% in Q2 2025, selling an estimated $815 and leaving 345 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

First Horizon Advisors first reported a position in XENE in Q1 2023 and has held it in 10 quarters since. The position peaked at $26.3K in Q4 2023. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

First Horizon Advisors held 345 shares of Xenon Pharmaceuticals worth $10.8K as of Q2 2025.
First Horizon Advisors sold 25 Xenon Pharmaceuticals shares in Q2 2025, an estimated $815.
Xenon Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1651 holding.
First Horizon Advisors first reported a position in Xenon Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
First Horizon Advisors's Xenon Pharmaceuticals position peaked at $26.3K in Q4 2023.
206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.